Total: $105.1 million

Top 3 drugs
Crestor: $32.7 million
Nexium: $29.2 million
Symbicort: $27.8 million
Watch the Crestor TV commercial here >>

AstraZeneca's ($AZN) Crestor remains a substantial seller and doesn't lose its patent in the U.S. until 2016, but it's losing steam nonetheless. Its premium branded drug price gives payers reason to move patients to generic Lipitor, although the company says those defections are stabilizing. U.S. sales fell 4% to $1.4 billion in the first half of the year. U.S. sales of the popular upset stomach drug Nexium held out a bit better but were still off in the first half, down 1% to $1.8 billion. Under a patent settlement with Teva, the company will get generic competition for Nexium next year, and in the meantime, it is fighting a rearguard action against Hanmi Pharmaceutical's modified version, the almost-copycat drug Esomezol, which uses a different salt form than AstraZeneca's pill. Meanwhile, the drugmaker, which has been hacking jobs and making deals to get back to growth, saw U.S. sales of respiratory drug Symbicort, which it also advertised aggressively, jump 24% in H1 2013 to $576 million.


Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.